Year called to bar: 1985 (New York); 1989 (Massachusetts)
Cheryl is the leader of Torys’ Life Sciences practice, a cross-border group in both Canada and the United States. She represents the entire spectrum of biotech, medical device and health technology companies, from start-ups to large public companies, as well as venture capitalists, investment banks and academic medical centers. Cheryl is widely recognized for her long track record of helping life sciences companies at all stages formulate and evolve their domestic and international growth strategies, source capital, and develop and optimize their corporate and tax structures. Cheryl has extensive experience advising clients on venture and later-stage financings, IPOs, mergers and acquisitions, licensing transactions and joint ventures or alliances with strategic partners. Cheryl has been named WXN’s Canada’s Top 100 Most Powerful Women four times and inducted into its Hall of Fame. She has been repeatedly recognized by LMG Life Sciences as the Canadian Finance & Corporate Attorney of the Year and was one of five shortlisted by LMG Life Sciences for US Venture Capital Lawyer of the Year. She is also ranked in Band 1 by Chambers Canada for life sciences corporate/commercial. Prior to joining Torys, Cheryl led the 85-attorney life sciences group of a US law firm.
On July 17, 2017, Norgine B.V., a European specialist pharmaceutical company, acquired all issued and outstanding shares of Merus Labs International Inc. (Merus), pursuant to a plan of arrangement for $1.65 per common share in cash, including the assumption of all debt obligations, for a total enterprise value of approximately $342 million.
On April 21, 2015, Concordia Healthcare Corp. (Concordia), a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, acquired 18 products from Covis Pharma S.à.r.l and Covis Injectables, S.à.r.l (collectively, Covis). The purchase price of US$1.2 billion was paid in cash at closing.